EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice

Shiliang Ji, Yijie Wu, Ruifang Zhu, Dongkai Guo, Yiguo Jiang, Lifeng Huang, Xinwei Ma, Liqiang Yu

Gerontology · 2023 · 69 (9) · 1065-1075

DOI: 10.1159/000531194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gerontology, online erschienen am 07.06.2023. Verfasst von Shiliang Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China, dg21300014@smail.nju.edu.cn. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alzheimer’s disease (AD) is a major public health concern worldwide, but there are still no drugs available that treat it effectively. Previous studies have shown that phenylethanoid glycosides have pharmacological effects, which include anti-AD properties, but the underlying mechanisms by which they ameliorate AD symptoms remain unknown.

Methods

In this study, we used an APP/PS1 AD mouse model to explore the function and mechanisms underlying savatiside A (SA) and torenoside B (TB) in the treatment of AD. SA or TB (100 mg·kg-1·d-1) was orally administered to 7-month-old APP/PS1 mice for 4 weeks. Cognitive and memory functions were measured using behavioral experiments (including the Morris water maze test and the Y-maze spontaneous alternation test). Molecular biology experiments (including Western blotting, immunofluorescence, and enzyme-linked immunosorbent assays) were used to detect any corresponding changes in signaling pathways.

Results

The results showed that SA or TB treatment could significantly reduce cognitive impairment in APP/PS1 mice. We also showed that chronic treatment with SA/TB could prevent spine loss, synaptophysin immunoreactivity, and neuronal loss in mice, thereby improving synaptic plasticity and moderating learning and memory deficits. SA/TB administration also promoted the expression of synaptic proteins in APP/PS1 mouse brains and upregulated phosphorylation of proteins in the cyclic adenosine monophosphate (cAMP)/CREB/brain-derived neurotrophic growth factor (BDNF) pathway that are responsible for synaptic plasticity. Additionally, chronic SA/TB treatment increased the levels of BDNF and nerve growth factor (NGF) in the brains of APP/PS1 mice. Both astrocyte and microglia volumes, as well as the generation of amyloid β, were also decreased in SA/TB-treated APP/PS1 mice compared to control APP/PS1 mice.

Conclusion

In summary, SA/TB treatment was associated with activation of the cAMP/CREB/BDNF pathway and increased BDNF and NGF expression, indicating that SA/TB improves cognitive functioning via nerve regeneration. SA/TB is a promising candidate drug for the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseMiceAnimalsMice, TransgenicBrain-Derived Neurotrophic FactorNerve Growth FactorHippocampusNeuronal PlasticityBrainMaze LearningAdenosine MonophosphateDisease Models, Animal

Stichwörter der Autor:innen

Alzheimer’s diseaseCyclic adenosine monophosphate-signaling pathwayNeurotrophyPhenylethanoid glycosidesSynapse plasticity

Substanzen

Amyloid beta-PeptidesBrain-Derived Neurotrophic FactorNerve Growth FactorAdenosine Monophosphate

Autor:innen und Institutionen

  • Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China, dg21300014@smail.nju.edu.cn.
  • Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
  • Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
  • Department of Medical Imaging, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
  • Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Zitieren

APA

Ji, S., Wu, Y., Zhu, R., Guo, D., Jiang, Y., Huang, L., Ma, X., & Yu, L. (2023). Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice. Gerontology, 69(9), 1065-1075. https://doi.org/10.1159/000531194

Vancouver

Ji S, Wu Y, Zhu R, Guo D, Jiang Y, Huang L, et al. Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice. Gerontology. 2023;69(9):1065-1075. doi:10.1159/000531194

BibTeX
@article{Ji2023,
  author = {Ji, Shiliang and Wu, Yijie and Zhu, Ruifang and Guo, Dongkai and Jiang, Yiguo and Huang, Lifeng and Ma, Xinwei and Yu, Liqiang},
  title = {Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice},
  journal = {Gerontology},
  year = {2023},
  volume = {69},
  number = {9},
  pages = {1065--1075},
  doi = {10.1159/000531194}
}
Kostenlos starten →